TapVision AI is developing an FDA-regulated platform that integrates eye-tracking, EEG, and behavioral biomarkers to deliver objective, scalable autism spectrum disorder assessment — reducing diagnostic delays from years to minutes.
The Challenge
Current gold-standard tools like the ADOS-2 require highly trained clinicians, 2–3 hour assessments, and months-long waitlists — leaving millions of families without answers during the most critical developmental window.
Gold-standard ADOS-2 requires specialized training and introduces significant inter-rater variability in scoring.
Specialist shortages mean rural and underserved communities wait 18–36 months for a first evaluation.
No FDA-cleared biological or physiological measure exists for ASD diagnosis — assessment remains purely behavioral and subjective.
Average time from a parent's first developmental concern to a child receiving a formal ASD diagnosis in the United States — a gap that directly delays access to early intervention therapies proven to improve outcomes.
The Platform
TapVision's platform acquires and fuses three complementary physiological and behavioral data streams — each independently validated as ASD-relevant — into a single, interpretable biomarker output.
Quantifies fixation patterns, social scene scanning, saccade dynamics, and orienting responses to social stimuli. Children with ASD exhibit characteristic gaze avoidance and atypical visual attention patterns detectable in milliseconds.
Extracts EEG-derived spectral and event-related potential features associated with ASD neural circuits — including frontal theta-band power, mu suppression, N170 face processing, and functional connectivity signatures.
Captures motor timing, sensory processing latencies, adaptive response patterns, and social attention behaviors through structured tablet-based tasks designed to elicit and quantify ASD-relevant behavioral phenotypes.
How It Works
Leadership
Practicing physician with direct clinical expertise in autism spectrum disorder assessment — TapVision is built from firsthand understanding of diagnostic gaps and clinical workflow constraints.
Active SFARI Base researcher. SPARK cohort application submitted. SFARI Base account active. ORCID: 0009-0005-2788-3223. IRB protocol in preparation.
TapVision AI LLC is a Delaware-registered company pursuing FDA De Novo device classification. SBIR Phase I application in preparation. Patents pending.
TapVision AI LLC operates as an independent subsidiary within a multi-entity healthcare technology holding structure, maintaining separation between device development and clinical practice.
Get in Touch
Whether you're a researcher, clinician, investor, or partner — we'd like to hear from you.